2014•PubMedRequires access
[Outcome analysis of alternative donor allogeneic hematopoietic cell transplantation in the treatment of 19 severe aplastic anemia patients].
Xin Chen, Jialin Wei, Yong Huang, Yi He, Donglin Yang, Erlie Jiang, Qiaoling Ma, Jianfeng Yao, Lukun Zhou, Xiaoting Lin, Yuyan Shen, Xin Yang, Zhao Wang, Sizhou Feng, Mingzhe Han
Open publisher page 3 citations
Abstract
OBJECTIVE: To evaluate the efficacy of alternative donor allogeneic hematopoietic stem cell transplantation (AD allo-HSCT) in the treatment of severe aplastic anemia (SAA). METHODS: Retrospective analysis of the clinical data of 19 SAA patients received AD allo-HSCT from May 2003 to December 2012. Of them, 12 received haploidentical HSCT (haplo-HSCT), 7 received unrelated donor transplantation. The conditioning regimen was CY+ATG+Flu±Ara-C±Bu/Mel, the GVHD preventing regimen was MMF+MTX+CSA/FK506; the median reinfusion quantity of CD34+ was 3.10(2.11-4.38)×10⁶/kg in allo-BMT and 4.90(2.08-6.88)×10⁶/kg in allo-PBSCT. RESULTS: Hematopoiesis reconstitution was achieved in all 19 patients. Twelve patients developed acute graft-versus-host disease (aGVHD), and 7 developed chronic GVHD (cGVHD). Graft rejection (GR) was occurred in one patient. The median follow-up time was 13(3-115) months. Thirteen patients survived, and the prospective 5-year overall survival rate is (67.5±11.0)%. CONCLUSION: AD allo-HSCT can be used as an alternative therapy for SAA patients without HLA matched sibling donor.